Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 169 of 169 results for metastatic breast cancer

  1. Thousands of appointments released for the NHS without compromising safety

    Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term

    News
    Last updated
    23 January 2024

  2. NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer

    Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.

    News
    Last updated
    1 October 2024

  3. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

    News
    Last updated
    29 July 2024

  4. NICE responds to failure of talks to reach price agreement on Enhertu

    Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

    News
    Last updated
    19 November 2024